These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 16784865)
1. Discovery of heteroaryl sulfonamides as new EP1 receptor selective antagonists. Naganawa A; Matsui T; Saito T; Ima M; Tatsumi T; Yamamoto S; Murota M; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M Bioorg Med Chem; 2006 Oct; 14(19):6628-39. PubMed ID: 16784865 [TBL] [Abstract][Full Text] [Related]
2. Discovery of new chemical leads for selective EP1 receptor antagonists. Naganawa A; Saito T; Nagao Y; Egashira H; Iwahashi M; Kambe T; Koketsu M; Yamamoto H; Kobayashi M; Maruyama T; Ohuchida S; Nakai H; Kondo K; Toda M Bioorg Med Chem; 2006 Aug; 14(16):5562-77. PubMed ID: 16697646 [TBL] [Abstract][Full Text] [Related]
3. Further optimization of sulfonamide analogs as EP1 receptor antagonists: synthesis and evaluation of bioisosteres for the carboxylic acid group. Naganawa A; Matsui T; Ima M; Saito T; Murota M; Aratani Y; Kijima H; Yamamoto H; Maruyama T; Ohuchida S; Nakai H; Toda M Bioorg Med Chem; 2006 Nov; 14(21):7121-37. PubMed ID: 16879970 [TBL] [Abstract][Full Text] [Related]
4. Identification of novel glycine sulfonamide antagonists for the EP1 receptor. McKeown SC; Hall A; Blunt R; Brown SH; Chessell IP; Chowdhury A; Giblin GM; Healy MP; Johnson MR; Lorthioir O; Michel AD; Naylor A; Lewell X; Roman S; Watson SP; Winchester WJ; Wilson RJ Bioorg Med Chem Lett; 2007 Mar; 17(6):1750-4. PubMed ID: 17236765 [TBL] [Abstract][Full Text] [Related]
5. Optimization of sulfonamide derivatives as highly selective EP1 receptor antagonists. Naganawa A; Matsui T; Ima M; Yoshida K; Tsuruta H; Yamamoto S; Yamamoto H; Okada H; Maruyama T; Nakai H; Kondo K; Toda M Bioorg Med Chem; 2006 Dec; 14(23):7774-89. PubMed ID: 16931028 [TBL] [Abstract][Full Text] [Related]
6. Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists. Asada M; Obitsu T; Kinoshita A; Nakai Y; Nagase T; Sugimoto I; Tanaka M; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M Bioorg Med Chem Lett; 2010 Apr; 20(8):2639-43. PubMed ID: 20346663 [TBL] [Abstract][Full Text] [Related]
7. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives. Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J; Winyard L Bioorg Med Chem Lett; 2007 Feb; 17(4):916-20. PubMed ID: 17175160 [TBL] [Abstract][Full Text] [Related]
8. Peri-substituted hexahydro-indolones as novel, potent and selective human EP3 receptor antagonists. O'Connell M; Zeller W; Burgeson J; Mishra RK; Ramirez J; Kiselyov AS; Andrésson T; Gurney ME; Singh J Bioorg Med Chem Lett; 2009 Feb; 19(3):778-82. PubMed ID: 19121942 [TBL] [Abstract][Full Text] [Related]
9. 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists: Structure-activity relationships of 4- and 5-substituted benzoic acid derivatives. Hall A; Brown SH; Chessell IP; Chowdhury A; Clayton NM; Coleman T; Giblin GM; Hammond B; Healy MP; Johnson MR; Metcalf A; Michel AD; Naylor A; Novelli R; Spalding DJ; Sweeting J Bioorg Med Chem Lett; 2007 Feb; 17(3):732-5. PubMed ID: 17098427 [TBL] [Abstract][Full Text] [Related]
10. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 3: Synthesis, metabolic stability, and biological evaluation of optically active analogs. Asada M; Obitsu T; Kinoshita A; Nagase T; Yoshida T; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Nakai H; Toda M; Tobe Y Bioorg Med Chem; 2010 May; 18(9):3212-23. PubMed ID: 20385498 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a series of acrylic acids and their derivatives as chemical leads for selective EP3 receptor antagonists. Asada M; Obitsu T; Nagase T; Sugimoto I; Yamaura Y; Sato K; Narita M; Ohuchida S; Nakai H; Toda M Bioorg Med Chem; 2009 Sep; 17(18):6567-82. PubMed ID: 19700331 [TBL] [Abstract][Full Text] [Related]
12. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Giblin GM; Bit RA; Brown SH; Chaignot HM; Chowdhury A; Chessell IP; Clayton NM; Coleman T; Hall A; Hammond B; Hurst DN; Michel AD; Naylor A; Novelli R; Scoccitti T; Spalding D; Tang SP; Wilson AW; Wilson R Bioorg Med Chem Lett; 2007 Jan; 17(2):385-9. PubMed ID: 17084082 [TBL] [Abstract][Full Text] [Related]
13. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist. Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366 [TBL] [Abstract][Full Text] [Related]
14. Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists. Hategan G; Polozov AM; Zeller W; Cao H; Mishra RK; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J Bioorg Med Chem Lett; 2009 Dec; 19(23):6797-800. PubMed ID: 19836233 [TBL] [Abstract][Full Text] [Related]
15. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 1: discovery and exploration of the carboxyamide side chain. Asada M; Obitsu T; Nagase T; Tanaka M; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M Bioorg Med Chem; 2010 Jan; 18(1):80-90. PubMed ID: 20004584 [TBL] [Abstract][Full Text] [Related]
16. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. part 2: optimization of the side chains to improve in vitro and in vivo potencies. Asada M; Iwahashi M; Obitsu T; Kinoshita A; Nakai Y; Onoda T; Nagase T; Tanaka M; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Ohuchida S; Nakai H; Toda M Bioorg Med Chem; 2010 Feb; 18(4):1641-58. PubMed ID: 20129791 [TBL] [Abstract][Full Text] [Related]
17. 3,4-Disubstituted indole acylsulfonamides: a novel series of potent and selective human EP3 receptor antagonists. Zhou N; Zeller W; Krohn M; Anderson H; Zhang J; Onua E; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J Bioorg Med Chem Lett; 2009 Jan; 19(1):123-6. PubMed ID: 19022669 [TBL] [Abstract][Full Text] [Related]
18. PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity. Carrasco E; Casper D; Werner P J Neurosci Res; 2007 Nov; 85(14):3109-17. PubMed ID: 17868147 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel aminothiadiazole amides as selective EP(3) receptor antagonists. Hilfiker MA; Wang N; Hou X; Du Z; Pullen MA; Nord M; Nagilla R; Fries HE; Wu CW; Sulpizio AC; Jaworski JP; Morrow D; Edwards RM; Jin J Bioorg Med Chem Lett; 2009 Aug; 19(15):4292-5. PubMed ID: 19487124 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 1. Synthesis and SAR of alpha,alpha-dimethylglycine sulfonamides. Fattori D; Rossi C; Fincham CI; Berettoni M; Calvani F; Catrambone F; Felicetti P; Gensini M; Terracciano R; Altamura M; Bressan A; Giuliani S; Maggi CA; Meini S; Valenti C; Quartara L J Med Chem; 2006 Jun; 49(12):3602-13. PubMed ID: 16759102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]